Euro Panel Q1FY27: revenue +14% YoY but PAT falls 16% as costs squeeze margins

Euro Panel Products' consolidated revenue grew 14.3% YoY to ₹119.81 Cr (₹104.84 Cr in Q1 FY26) but consolidated PAT fell 16.4% YoY to ₹4.78 Cr (₹5.72 Cr), with EPS down to ₹1.95 from ₹2.34. Sequentially, both lines are weaker — revenue -15.1% and PAT -43.9% versus the seasonally stronger Q4 FY26 (₹141.09 Cr revenue, ₹8.52 Cr PAT) — so the QoQ decline should not be read as deterioration; it is the swing back from a strong March quarter. The YoY profit decline despite topline growth is the story: PBT margin compressed to 5.67% from 7.49%, and operating margin (revenue less opex, adding back finance cost and depreciation) softened to 10.65% from 11.33% a year ago, roughly flat against Q4's 10.70%. The margin squeeze traces mainly to costs growing faster than revenue: employee benefit expense rose 29.9% YoY (₹8.58 Cr to ₹11.14 Cr) and finance costs rose 21.4% YoY (₹3.07 Cr to ₹3.72 Cr), both outpacing the 14% topline growth, while material costs stayed roughly proportionate. Standalone PAT of ₹4.96 Cr fell a smaller 13.4% YoY versus consolidated's 16.4% decline, meaning the newly consolidated Euro Sealant and Qatar trading subsidiaries were a modest net drag this quarter rather than a contributor — consistent with the auditor's note that the Qatar unit posted a small net loss (₹18.63 lakh) on ₹18.86 lakh of revenue. Management gives no formal guidance on record and no prior concall commentary exists in our data, so there is no outlook to grade this print against; street/analyst estimates for this small-cap were not found in a search (only an unrelated company, Euro Pratik, surfaced). The quarter's other developments — incorporation of Eurobond Dimensions Pvt Ltd (70% stake, certified July 15, 2026) and commissioning of 3.6 MW of solar infrastructure (July 28, 2026) — are capacity/cost-structure moves whose financial impact isn't yet visible in this quarter's numbers. The filing also flags rain-related damage to factory inventory in Gujarat, with the claim quantum still being assessed with insurers, an unresolved item to track into Q2.